Skip to Content
A15 / P15
NCODA Oncology and Hematology Meeting Abstracts | Volume 2 | Supplement 1
Publication Date: April 7, 2026

Repurposing sodium-glucose cotransporter-2 inhibitors for the treatment of prostate cancer

Authors:

Lynn Cruz Lopategui1; Aarahana Shrestha, PhD1; Subrata Deb, PhD1; Debasish Basak, PhD1

Organization / Company:

1Larkin University

NCODA Oncol Hematol Meet Abstr. 2026;2(suppl 1):abstr 15.

Background:

Prostate cancer (PCa) is the second most common malignancy among men worldwide. A hallmark of PCa is metabolic reprogramming, characterized by increased glucose uptake to support rapid tumor growth. Sodium–glucose cotransporter-2 (SGLT2) inhibitors are a relatively new class of antidiabetic agents that have demonstrated antitumor effects by disrupting glucose uptake and cellular energetics in various tumor models. By lowering glucose and insulin levels, improving insulin sensitivity, and reducing chronic inflammation, these agents create a metabolically unfavorable environment for tumor progression.

 

Objectives:
  • Describe the antitumor effects of the SGLT2 inhibitor canagliflozin on PCa cell viability and clonogenic growth across androgen-dependent and androgen-independent models.
  • Evaluate the potential role of metabolic modulation through SGLT2 inhibition as a therapeutic strategy for prostate cancer, including opportunities for drug repurposing in patients with type 2 diabetes.

 

Research Question:

This study aimed to evaluate the antitumor potential of canagliflozin, an SGLT-2 inhibitor in PCa.

 

Study Design:

We performed cell viability and clonogenic assays using three well-characterized human PCa cell lines that were selected to model different clinical stages and treatment responses. DU145 and PC-3 are androgen-independent cell lines commonly used as in vitro models of castration-resistant prostate cancer (CRPC), which represents the advanced disease stage where tumors no longer respond to androgen deprivation therapy. Lymph node carcinoma of the prostate (LNCaP) is androgen-dependent and serves as a model for hormone-sensitive PCa, representative of earlier-stage disease where androgen receptor signaling remains a key driver of tumor growth. This selection allowed evaluation of canagliflozin’s antitumor potential across clinically distinct disease states. Canagliflozin was dissolved in dimethyl sulfoxide (DMSO), and control groups received an equivalent concentration of DMSO alone to ensure assay consistency.

 

Methods:

Cells were cultured and allowed to adhere for 24 hours before treatment. They were then exposed to increasing concentrations of canagliflozin (0.1– 50 μM) for 72 hours. Cell viability was then assessed using the methyl thiazolyl tetrazolium (MTS) assay, which estimates the number of viable cells based on the biochemical reduction of a tetrazolium compound into a colored product by metabolically active cells. After addition of the MTS reagent, cells were incubated at 37ÅãC for approximately 2 hours, and absorbance was measured at 490 nm using a SpectraMax190. M-Series Multi-Mode Microplate Reader. For clonogenic assays, 12-well plates were seeded at 1000–2000 cells/ well. Cells were incubated overnight, followed by canagliflozin treatment (0.1– 50 μM). Then cells were incubated for approximately 7 days or until colonies of at least 50 cells were visible in untreated wells. These cells were fixed, stained with crystal violet, and colonies were then counted.

 

Results:

Canagliflozin demonstrated a dose-dependent reduction in PCa cell viability and colony forming capacity, indicating a potent antiproliferative effect. Notably, this cytotoxicity and lower colony formation occurred independently of androgen receptor signaling.

 

Conclusions:

This study demonstrates that SGLT2 inhibition with canagliflozin significantly reduces viability and colony forming ability in both androgen dependent and androgen-independent PCa cell lines, underscoring its potential applicability across distinct clinical stages of the disease. The findings support the repurposing of SGLT2 inhibitors, particularly in patients with concurrent type 2 diabetes, where metabolic modulation could provide dual benefit. Future studies will include mechanistic studies assessing apoptosis, cell cycle regulation, glucose uptake inhibition, and invasion and migration potential. Translational studies will aim to confirm these effects in vivo using PCa xenograft models and to explore combination strategies with standard-of-care therapies. Collectively, these steps aim to advance SGLT2 inhibition toward clinical evaluation as part of an integrated metabolic-targeted strategy for PCa management.

Funding: Not applicable.

A15 / P15